Document Type : Original Article


1 Department of Pathology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye

2 Department of Virology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye

3 Department of Pathology, Faculty of Veterinary Medicine, Van Yuzuncu Yil University, Van, Türkiye

4 Health Sciences Institute, Kafkas University, Kars, Türkiye


In this study, it was aimed to investigate the association between inflammatory reaction of tumoral microenvironments with interleukin responses in ovine pulmonary adenocarcinomas (OPAs). Material of the study consisted of 26 sheep lung tissue samples being brought to the Pathology Department for routine diagnosis. Cases were collected between years 2009 - 2021; pre-diagnosis was based on clinical symptoms, anamnesis and gross lesion of the lungs. These tissues were designated in two groups as control (n = 6) and OPA (n = 20) groups. Choice of immunohistochemical staining was avidin-biotin peroxidase method. Reverse transcription polymerase chain reaction (RT-PCR) was used to confirm Jaagsiekte sheep retrovirus from paraffin-embedded tissues. On gross examination of OPAs, lesions seen were mostly in the caudal lobes of the lung, 1.00 – 2.00 cm in diameter as gray-white consolidated foci and in microscopic observation, tumor cells showed acinar, papillary or mixed growths. No expressions of interleukin (2 and 8) were observed in the control group. All OPAs cases were positive for interleukins (2 and 8) expressions. A total of eight tissue samples were detected as positives through RT-PCR. In conclusion, in this study, it was determined that interleukin-2 and interleukin-8 were produced from tumor microenvironment elements, especially tumor-associated macrophages, and these interleukins showed pro-inflammatory effects. Interleukins and the inflammatory reaction may promote the development of OPA.


  1. İlhan F, Vural SA, Yıldırım S, et al. Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis. J Vet Diagn Invest 2016; 28(3): 249-256.
  2. Karagianni AE, Vasoya D, Finlayson et al. Transcriptional response of ovine lung to infection with Jaagsiekte sheep retrovirus. J Virol 2019; 93(21): e00876-19. doi: 10.1128/JVI.00876-19.
  3. Larruskain A, Esparza-Baquer A, Minguijón E, et al. SNPs in candidate genes MX dynamin-like GTPase and chemokine (C-C motif) receptor-5 are associated with ovine pulmonary adenocarcinoma progression in Latxa sheep. Anim Genet 2015; 46(6): 666-675.
  4. Beytut E, Sözmen M, Ergínsoy S. Immunohistochemical detection of pulmonary surfactant proteins and retroviral antigens in the lungs of sheep with pulmonary adenomatosis. J Comp Pathol 2009; 140(1): 43-53.
  5. Özkan C, Yıldırım S, Huyut Z, et al. Selected tumour biomarker levels in sheep with pulmonary adenomatosis. J Vet Res 2020; 64(1): 39-44.
  6. Toma C, Bâlteanu VA, Tripon S, et al. Exogenous Jaagsiekte sheep retrovirus type 2 (exJSRV2) related to ovine pulmonary adenocarcinoma (OPA) in Romania: prevalence, anatomical forms, pathological description, immunophenotyping and virus identification. BMC Vet Res 2020; 16: 296. doi: 10.1186/s12917-020-02521-1.
  7. De Las Heras M, Borobia M, Ortín A. Neoplasia-associated wasting diseases with economic relevance in the sheep industry. Animals (Basel) 2021; 11(2): 381. doi: 10.3390/ani11020381.
  8. Gray ME, Meehan J, Sullivan P, et al. Ovine pulmonary adenocarcinoma: a unique model to improve lung cancer research. Front Oncol 2019; 9: 335. doi: 10.3389/fonc.2019.00335.
  9. Larruskain A, Minguijón E, Arostegui I, et al. Microsatellites in immune-relevant regions and their associations with Maedi-Visna and ovine pulmonary adenocarcinoma viral diseases. Vet Immunol Immunopathol 2012; 145(1-2): 438-446.
  10. Lee AM, Wolfe A, Cassidy JP, et al. First confirmation by PCR of Jaagsiekte sheep retrovirus in Ireland and prevalence of ovine pulmonary adenocarcinoma in adult sheep at slaughter. Ir Vet J 2017; 70: 33. doi: 10.1186/s13620-017-0111-z.
  11. Dutkowska A, Szmyd B, Kaszkowiak M, et al. Expression of inflammatory interleukins and selected miRNAs in non-small cell lung cancer. Sci Rep 2021; 11: 5092. doi: 10.1038/s41598-021-84408-1.
  12. Li R, Ong SL, Tran LM, et al. Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Sci Rep 2020; 10(1): 377. doi: 10.1038/s41598-019-57285-y. Erratum in: Sci Rep 2020; 10(1): 4386.
  13. Tian C, Lu S, Fan Q, et al. Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chin Med J (Engl) 2015; 128(1): 105-110.
  14. Tekpli X, Landvik NE, Anmarkud KH, et al. DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer. Cancer Immunol Immunother 2013; 62(2): 337-345.
  15. Liu Y, Wu BQ, Geng H, et al. Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma. Oncol Lett 2015; 10(3): 1315-1322.
  16. Petrella BL, Armstrong DA, Vincenti MP. Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells. Cancer Lett 2012; 325(2): 220-226.
  17. Umekawa K, Kimura T, Kudoh S, et al. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes 2013; 6: 139. doi: 10.1186/1756-0500-6-139.
  18. Bersanelli M, Buti S, Camisa R, et al. Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel) 2014; 6(4): 2035-2048.
  19. Han L, Jiang Q, Yao W, et al. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients. BMC Cancer 2018; 18: 725. doi: 10.1186/ s12885-018-4581-5.
  20. Mi D, Ren W, Yang K. Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis. Indian J Med Res 2016; 143(Supplement): S1-S10.
  21. Xu Y, Pan Y, Zhou Z. Recombinant human thrombo-poietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis 2019; 11(11): 4671-4681.
  22. Li L, Li D, Chen Y. miRNA-26a blocks interleukin-2-mediated migration and proliferation of non-small cell lung cancer cells via vascular cell adhesion molecule-1. Transl Cancer Res 2020; 9(3): 1768-1778.
  23. Rafrafi A, Chahed B, Kaabachi S, et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study. Hum Immunol 2013; 74(10): 1368-1374.
  24. Lee YJ, Lim T, Han MS, et al. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells. Oncol Rep 2017; 37(2): 1219-1226.
  25. Shiau MY, Fan LC, Yang SC, et al. Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adeno-carcinomas. PLoS One 2013; 8(1). e54423. doi: 10.1371/journal.pone.0054423.
  26. Sunaga N, Kaira K, Tomizawa Y, et al. Clinico-pathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Br J Cancer 2014; 110(8): 2047-2053.
  27. Pikor LA, Enfield KS, Cameron H, et al. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp 2011; (49): 2763. doi: 10.3791/2763.
  28. Mansour KA, Al-Husseiny SH, Kshash QH, et al. Clinical-histopathological and molecular study of ovine pulmonary adenocarcinoma in Awassi sheep in Al-Qadisiyah Province, Iraq. Vet World 2019; 12(3):
  29. Islas-Vazquez L, Aguilar-Cazares D, Galicia-Velasco M, et al. IL-6, NLR, and SII markers and their relation with alterations in CD8+ T-lymphocyte subpopulations in patients treated for lung adenocarcinoma. Biology (Basel) 2020; 9(11): 376. doi: 10.3390/ biology9110376.